Exelixis CEO Eyes Expanded Indications For Cabozantinib

 
• By Emily Hayes

In a video interview at the Biotech Showcase, Exelixis CEO Michael Morrissey discusses the recent launch of cabozantinib in first-line renal cell carcinoma and looks ahead to filing soon in liver cancer.

Mike Morrissey_Exelixis

More from Immuno-oncology

More from Anticancer